NasdaqGS - Nasdaq Real Time Price USD
Amgen Inc. (AMGN)
350.89 +3.88 (+1.12%)
As of 1:30:33 PM EDT. Market Open.
Trade Amgen on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for AMGN
- Previous Close
347.01 - Open
348.00 - Bid 351.67 x 100
- Ask 351.44 x 100
- Day's Range
346.00 - 353.19 - 52 Week Range
269.77 - 391.29 - Volume
728,485 - Avg. Volume
2,753,154 - Market Cap (intraday)
189.378B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
24.42 - EPS (TTM)
14.37 - Earnings Date (est.) Aug 4, 2026
- Forward Dividend & Yield 10.08 (2.90%)
- Ex-Dividend Date May 15, 2026
- 1y Target Est
352.77
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
AMGN
8.76%
S&P 500 (^GSPC)
7.38%
1-Year Return
AMGN
30.25%
S&P 500 (^GSPC)
20.65%
3-Year Return
AMGN
69.41%
S&P 500 (^GSPC)
69.04%
5-Year Return
AMGN
70.46%
S&P 500 (^GSPC)
72.28%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
187.28B
Enterprise Value
232.57B
Trailing P/E
24.15
Forward P/E
15.60
PEG Ratio (5yr expected)
2.29
Price/Sales (ttm)
5.06
Price/Book (mrq)
20.38
Enterprise Value/Revenue
6.25
Enterprise Value/EBITDA
13.95
Financial Highlights
Profitability and Income Statement
Profit Margin
20.96%
Return on Assets (ttm)
8.35%
Return on Equity (ttm)
101.32%
Revenue (ttm)
37.22B
Net Income Avi to Common (ttm)
7.8B
Diluted EPS (ttm)
14.37
Balance Sheet and Cash Flow
Total Cash (mrq)
12.04B
Total Debt/Equity (mrq)
623.75%
Levered Free Cash Flow (ttm)
7.44B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreRaising EPS estimates for 2026 and 2027
Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Prolia, Enbrel, Otezla, Repatha, Xgeva, Tepezza, Evenity, Blincyto, Kyprolis, Krystexxa, and Nplate. The shares are a component of the S&P 500.
RatingPrice TargetThe major indices are lower at midday on Tuesday. Bond yields continue to move
The major indices are lower at midday on Tuesday. Bond yields continue to move up on the higher-than-expected inflation numbers from last week, and crude oil is now at $103 per barrel. The yield on the 10-year note is at 4.67%. The VIX volatility index is at 18.
Amgen Earnings: Steady First Quarter, Although Pipeline Cuts Concentrate Risk
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetRaising price target to $400
Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Prolia, Enbrel, Otezla, Repatha, Xgeva, Tepezza, Evenity, Blincyto, Kyprolis, Krystexxa, and Nplate. The shares are a component of the S&P 500.
RatingPrice Target